Quantum Biopharma (NASDAQ:QNTM) Earns Sell (E+) Rating from Weiss Ratings

Quantum Biopharma (NASDAQ:QNTM)‘s stock had its “sell (e+)” rating restated by research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Separately, Singular Research upgraded Quantum Biopharma to a “moderate buy” rating in a research report on Wednesday, June 18th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Quantum Biopharma Stock Performance

Shares of QNTM stock opened at $15.77 on Wednesday. Quantum Biopharma has a 52-week low of $2.70 and a 52-week high of $38.25. The firm has a market capitalization of $60.18 million, a PE ratio of -1.12 and a beta of 0.70. The stock has a fifty day simple moving average of $18.88 and a two-hundred day simple moving average of $15.66.

Quantum Biopharma shares are scheduled to split on Monday, October 27th. The 2-1 split was recently announced. The newly minted shares will be distributed to shareholders after the closing bell on Sunday, October 26th.

Quantum Biopharma (NASDAQ:QNTM) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($3.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($3.06). On average, sell-side analysts forecast that Quantum Biopharma will post -3.27 EPS for the current fiscal year.

Institutional Trading of Quantum Biopharma

An institutional investor recently bought a new position in Quantum Biopharma stock. Steward Partners Investment Advisory LLC purchased a new stake in shares of Quantum Biopharma Ltd. (NASDAQ:QNTM) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 3,100 shares of the company’s stock, valued at approximately $63,000. Steward Partners Investment Advisory LLC owned approximately 0.11% of Quantum Biopharma as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 1.24% of the company’s stock.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.